Article

TP53 knockout in MCF7 breast cancer cells induces sensitivity to fluoropyrimidine drugs

2022-02-11

Abstract excerpt

TP53 mutations are present in all molecular subtypes of breast cancer and often correlate with decreased survival; however, few therapeutic options exist for patients with TP53-mutant breast cancers. To discover therapeutic strategies for these patients, we investigated the sensitivity of 129 FDA-approved chemotherapies to TP53-KO and TP53-WT MCF7 breast adenocarcinoma cells and found p53 loss to confer sensitivit...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 15f56b13-c8ed-5b9e-bc59-2347000c05ba
DOI: 10.1101/2022.02.10.479997

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

TP53 knockout in MCF7 breast cancer cells induces sensitivity to fluoropyrimidine drugsDOI 10.1101/2022.02.10.479997Read

Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair.Semantic proximity Read

Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 InhibitionSemantic proximity Read

Tailoring Chemotherapy for the African-Centric S47 Variant of TP53.Semantic proximity Read

Inhibition of GPX4 Induces the Death of p53-Mutant Triple-Negative Breast CancerSemantic proximity Read

Cancer therapeutic targeting using mutant–p53-specific siRNAsSemantic proximity Read

Inhibition of GPX4 Induces the Death of p53-Mutant Triple-Negative Breast Cancer CellsSemantic proximity Read

Inhibition of GPX4 induces the death of p53-mutant triple-negative breast cancer cells.Semantic proximity Read

Loss of Uracil DNA Glycosylase Selectively Resensitizes p53-Mutant and -Deficient Cells to 5-FdU.Semantic proximity Read

Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide.Semantic proximity Read

PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.Semantic proximity Read

Alterations in the p53 isoform ratio govern breast cancer cell fate in response to DNA damageSemantic proximity Read

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007Semantic proximity Read